Cargando…

Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. In a prospective multicentric study, we identify IL-3 as an independent prognostic marker for the outcome during SARS-CoV-2 infections. Specifically, low plasma IL-3 levels is associated with increased severit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bénard, Alan, Jacobsen, Anne, Brunner, Maximilian, Krautz, Christian, Klösch, Bettina, Swierzy, Izabela, Naschberger, Elisabeth, Podolska, Malgorzata J., Kouhestani, Dina, David, Paul, Birkholz, Torsten, Castellanos, Ixchel, Trufa, Denis, Sirbu, Horia, Vetter, Marcel, Kremer, Andreas E., Hildner, Kai, Hecker, Andreas, Edinger, Fabian, Tenbusch, Matthias, Mühl-Zürbes, Petra, Steinkasserer, Alexander, Richter, Enrico, Streeck, Hendrik, Berger, Marc M., Brenner, Thorsten, Weigand, Markus A., Swirski, Filip K., Schett, Georg, Grützmann, Robert, Weber, Georg F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893044/
https://www.ncbi.nlm.nih.gov/pubmed/33602937
http://dx.doi.org/10.1038/s41467-021-21310-4
_version_ 1783652981942517760
author Bénard, Alan
Jacobsen, Anne
Brunner, Maximilian
Krautz, Christian
Klösch, Bettina
Swierzy, Izabela
Naschberger, Elisabeth
Podolska, Malgorzata J.
Kouhestani, Dina
David, Paul
Birkholz, Torsten
Castellanos, Ixchel
Trufa, Denis
Sirbu, Horia
Vetter, Marcel
Kremer, Andreas E.
Hildner, Kai
Hecker, Andreas
Edinger, Fabian
Tenbusch, Matthias
Mühl-Zürbes, Petra
Steinkasserer, Alexander
Richter, Enrico
Streeck, Hendrik
Berger, Marc M.
Brenner, Thorsten
Weigand, Markus A.
Swirski, Filip K.
Schett, Georg
Grützmann, Robert
Weber, Georg F.
author_facet Bénard, Alan
Jacobsen, Anne
Brunner, Maximilian
Krautz, Christian
Klösch, Bettina
Swierzy, Izabela
Naschberger, Elisabeth
Podolska, Malgorzata J.
Kouhestani, Dina
David, Paul
Birkholz, Torsten
Castellanos, Ixchel
Trufa, Denis
Sirbu, Horia
Vetter, Marcel
Kremer, Andreas E.
Hildner, Kai
Hecker, Andreas
Edinger, Fabian
Tenbusch, Matthias
Mühl-Zürbes, Petra
Steinkasserer, Alexander
Richter, Enrico
Streeck, Hendrik
Berger, Marc M.
Brenner, Thorsten
Weigand, Markus A.
Swirski, Filip K.
Schett, Georg
Grützmann, Robert
Weber, Georg F.
author_sort Bénard, Alan
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. In a prospective multicentric study, we identify IL-3 as an independent prognostic marker for the outcome during SARS-CoV-2 infections. Specifically, low plasma IL-3 levels is associated with increased severity, viral load, and mortality during SARS-CoV-2 infections. Patients with severe COVID-19 exhibit also reduced circulating plasmacytoid dendritic cells (pDCs) and low plasma IFNα and IFNλ levels when compared to non-severe COVID-19 patients. In a mouse model of pulmonary HSV-1 infection, treatment with recombinant IL-3 reduces viral load and mortality. Mechanistically, IL-3 increases innate antiviral immunity by promoting the recruitment of circulating pDCs into the airways by stimulating CXCL12 secretion from pulmonary CD123(+) epithelial cells, both, in mice and in COVID-19 negative patients exhibiting pulmonary diseases. This study identifies IL-3 as a predictive disease marker for SARS-CoV-2 infections and as a potential therapeutic target for pulmunory viral infections.
format Online
Article
Text
id pubmed-7893044
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78930442021-03-03 Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections Bénard, Alan Jacobsen, Anne Brunner, Maximilian Krautz, Christian Klösch, Bettina Swierzy, Izabela Naschberger, Elisabeth Podolska, Malgorzata J. Kouhestani, Dina David, Paul Birkholz, Torsten Castellanos, Ixchel Trufa, Denis Sirbu, Horia Vetter, Marcel Kremer, Andreas E. Hildner, Kai Hecker, Andreas Edinger, Fabian Tenbusch, Matthias Mühl-Zürbes, Petra Steinkasserer, Alexander Richter, Enrico Streeck, Hendrik Berger, Marc M. Brenner, Thorsten Weigand, Markus A. Swirski, Filip K. Schett, Georg Grützmann, Robert Weber, Georg F. Nat Commun Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. In a prospective multicentric study, we identify IL-3 as an independent prognostic marker for the outcome during SARS-CoV-2 infections. Specifically, low plasma IL-3 levels is associated with increased severity, viral load, and mortality during SARS-CoV-2 infections. Patients with severe COVID-19 exhibit also reduced circulating plasmacytoid dendritic cells (pDCs) and low plasma IFNα and IFNλ levels when compared to non-severe COVID-19 patients. In a mouse model of pulmonary HSV-1 infection, treatment with recombinant IL-3 reduces viral load and mortality. Mechanistically, IL-3 increases innate antiviral immunity by promoting the recruitment of circulating pDCs into the airways by stimulating CXCL12 secretion from pulmonary CD123(+) epithelial cells, both, in mice and in COVID-19 negative patients exhibiting pulmonary diseases. This study identifies IL-3 as a predictive disease marker for SARS-CoV-2 infections and as a potential therapeutic target for pulmunory viral infections. Nature Publishing Group UK 2021-02-18 /pmc/articles/PMC7893044/ /pubmed/33602937 http://dx.doi.org/10.1038/s41467-021-21310-4 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Bénard, Alan
Jacobsen, Anne
Brunner, Maximilian
Krautz, Christian
Klösch, Bettina
Swierzy, Izabela
Naschberger, Elisabeth
Podolska, Malgorzata J.
Kouhestani, Dina
David, Paul
Birkholz, Torsten
Castellanos, Ixchel
Trufa, Denis
Sirbu, Horia
Vetter, Marcel
Kremer, Andreas E.
Hildner, Kai
Hecker, Andreas
Edinger, Fabian
Tenbusch, Matthias
Mühl-Zürbes, Petra
Steinkasserer, Alexander
Richter, Enrico
Streeck, Hendrik
Berger, Marc M.
Brenner, Thorsten
Weigand, Markus A.
Swirski, Filip K.
Schett, Georg
Grützmann, Robert
Weber, Georg F.
Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
title Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
title_full Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
title_fullStr Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
title_full_unstemmed Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
title_short Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
title_sort interleukin-3 is a predictive marker for severity and outcome during sars-cov-2 infections
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893044/
https://www.ncbi.nlm.nih.gov/pubmed/33602937
http://dx.doi.org/10.1038/s41467-021-21310-4
work_keys_str_mv AT benardalan interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT jacobsenanne interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT brunnermaximilian interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT krautzchristian interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT kloschbettina interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT swierzyizabela interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT naschbergerelisabeth interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT podolskamalgorzataj interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT kouhestanidina interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT davidpaul interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT birkholztorsten interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT castellanosixchel interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT trufadenis interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT sirbuhoria interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT vettermarcel interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT kremerandrease interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT hildnerkai interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT heckerandreas interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT edingerfabian interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT tenbuschmatthias interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT muhlzurbespetra interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT steinkassereralexander interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT richterenrico interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT streeckhendrik interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT bergermarcm interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT brennerthorsten interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT weigandmarkusa interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT swirskifilipk interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT schettgeorg interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT grutzmannrobert interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections
AT webergeorgf interleukin3isapredictivemarkerforseverityandoutcomeduringsarscov2infections